Good
Partially Aligned
Patient Risk:
Info
Summary
Most claims are consistent with typical SUTENT labeling themes (indication as sunitinib; mechanism as tyrosine kinase inhibition; need for dosing schedules by indication; adverse effects; serious toxicity requiring monitoring). However, the provided FDA label excerpts focus only on hepatotoxicity (Section 5.1 and Table 2), so many other specific claims (exact schedules, common side effects list, and specific monitoring elements) cannot be confirmed from the supplied label text and are therefore treated as unsupported/insufficiently supported.
Category Scores
Accurate Statements
Sutent can cause severe hepatotoxicity resulting in liver failure or death and requires monitoring of liver function tests (ALT/AST and bilirubin) at baseline, during each cycle, and as clinically indicated.
Label excerpt 5.1 Hepatotoxicity: states severe hepatotoxicity resulting in liver failure or death; monitoring ALT/AST and bilirubin at baseline, during each cycle, and as clinically indicated.
For Grade 3 hepatotoxicity, interrupt/withhold until resolution to Grade ≤1 or baseline, then resume at a reduced dose.
Label excerpt 5.1 and Section 2 Dosage and Administration—2.4 (Table 2): Grade 3 withhold until resolution to Grade 0 to 1 or baseline, then resume at reduced dose.
For Grade 4 hepatotoxicity, discontinue SUTENT permanently.
Label excerpt 5.1 and Section 2 Dosage and Administration—2.4 (Table 2): Grade 4 permanently discontinue.
Sutent monitoring and dose interruption/discontinuation can depend on toxicity severity (e.g., hepatotoxicity grade and resolution).
Label excerpt 5.1: interrupt for Grade 3 until resolution then resume reduced dose; discontinue for Grade 4 and other severe scenarios; Table 2 specifies grade-based actions.
Unsupported Statements
Sutent is used to treat renal cell carcinoma (kidney cancer).
No FDA label excerpt for indications was provided in the prompt.
Sutent is used to treat gastrointestinal stromal tumor (GIST).
No FDA label excerpt for indications was provided in the prompt.
Sutent is used for GIST after treatment changes.
No FDA label excerpt for the specific GIST treatment-line language was provided in the prompt.
Sutent is a targeted cancer medicine (a tyrosine kinase inhibitor).
No mechanism-of-action excerpt was provided in the prompt.
Sutent blocks signaling from certain tyrosine kinases involved in tumor growth and blood-vessel formation.
No mechanism-of-action excerpt was provided in the prompt.
By inhibiting these pathways, Sutent can slow tumor progression.
No efficacy/clinical effect excerpt was provided in the prompt.
By inhibiting these pathways, Sutent can shrink tumors in some patients.
No efficacy/clinical effect excerpt was provided in the prompt.
Sutent dosing schedules depend on the specific cancer being treated.
No dosing schedule-by-indication excerpt was provided in the prompt; only hepatotoxicity modifications were excerpted.
The prescribing information provides the exact dose and an “on/off” schedule for each indication.
No excerpt containing dosing schedules or “on/off” language was provided in the prompt.
Common side effects reported for Sutent include fatigue.
No adverse reaction frequency list excerpt was provided in the prompt.
Common side effects reported for Sutent include diarrhea.
No adverse reaction frequency list excerpt was provided in the prompt.
Common side effects reported for Sutent include nausea.
No adverse reaction frequency list excerpt was provided in the prompt.
Common side effects reported for Sutent include decreased appetite.
No adverse reaction frequency list excerpt was provided in the prompt.
Common side effects reported for Sutent include hand-and-foot skin reaction.
No adverse reaction frequency list excerpt was provided in the prompt.
Common side effects reported for Sutent include hypertension.
No adverse reaction frequency list excerpt was provided in the prompt.
Common side effects reported for Sutent include changes in blood counts.
No adverse reaction frequency list excerpt was provided in the prompt.
Sutent can cause serious complications that require monitoring.
The prompt includes hepatotoxicity monitoring specifics, but does not provide other “serious complications” language or monitoring elements beyond hepatotoxicity in the excerpt provided.
Sutent can cause serious complications that sometimes require dose interruption.
Hepatotoxicity dose interruption is supported; however the claim is broad and not limited to hepatotoxicity, and no broader ‘serious complications’ sections were provided.
Sutent can cause heart-related effects.
No cardiotoxicity/heart-related excerpt was provided in the prompt.
Sutent can cause bleeding.
No bleeding/adverse event excerpt was provided in the prompt.
Sutent can cause certain liver or kidney problems.
Hepatotoxicity (liver) is supported; the kidney-problem part is not supported by the provided hepatotoxicity excerpt (renal failure is mentioned as part of severe hepatotoxicity context, but no standalone kidney-problems safety statement is provided).
Patients on Sutent are typically monitored with periodic checks that can include blood pressure.
No blood pressure monitoring excerpt was provided in the prompt.
Patients on Sutent are typically monitored with periodic checks that can include blood counts.
No blood count monitoring excerpt was provided in the prompt.
Patients on Sutent are typically monitored with periodic checks that can include liver function.
Liver function monitoring is specifically supported for hepatotoxicity; however the claim is phrased as a general ‘typically monitored’ list that includes multiple other monitors not provided. Treated as partially unsupported due to overbreadth.
Patients on Sutent are typically monitored with periodic checks that can include other labs relevant to safety.
No general monitoring labs excerpt was provided in the prompt.
Sutent monitoring is based on the medicine’s labeling and the patient’s overall condition.
No excerpt containing this general principle was provided in the prompt.
If a dose is missed or therapy needs to be interrupted for side effects, the correct steps depend on the prescribed schedule and the reason for interruption.
The hepatotoxicity interruption/resume/discontinue is supported; however the broad statement about missed dosing is not supported because no missed-dose guidance was provided in the prompt.
The prescribing information outlines dose-modification and interruption guidance for adverse reactions and missed dosing.
Dose modification for hepatotoxicity is supported; missed dosing guidance is not provided in the prompt.
Sutent is a marketed brand of sunitinib.
The prompt provides the active ingredient (sunitinib malate) but no explicit label excerpt confirming ‘marketed brand’ phrasing; however it is generally consistent with the product naming, so this is treated as insufficiently supported rather than contradicted.
Generic sunitinib products may be available depending on country and market status.
No label excerpt addresses generic availability.
Contradictions
Important Omissions
If the evaluation is specifically about hepatotoxicity management, the response did not clearly include the hepatotoxicity grade-based lab stopping/resume language details for recurrence of Grade 3 (permanent discontinuation for recurring Grade 3), or the label’s specific criteria about ALT/AST thresholds and that safety in those patients has not been established.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
Only hepatotoxicity management elements are label-supported by the supplied excerpts; many other safety/monitoring/adverse-effect claims are not supported by the provided label text, increasing the risk of incomplete or imprecise labeling alignment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims (indications, dosing schedule details, common adverse effects, and general monitoring elements) are not supported by the FDA label excerpts provided (which focus on hepatotoxicity).
Suggested Improvement
Limit hepatotoxicity-related claims to those directly supported by Section 5.1 and Table 2 (monitor ALT/AST and bilirubin; interrupt/withhold for Grade 3 until resolution and resume reduced dose; permanently discontinue Grade 4; include recurring Grade 3 and relevant ALT/AST threshold safety limitations if making detailed safety statements). Avoid or qualify other adverse effect and monitoring lists unless corresponding label excerpts are provided.